Cancer Research UK and Australian charity the Minderoo Foundation have committed £3 million to a clinical study designed to find better treatments for brain cancer. 

The research study will trial multiple new treatments for people in the UK living with glioblastoma.  

As part of the trial, every patient will have their genome sequenced, enabling researchers to target their treatment with greater precision. 

This will enable researchers to adapt the treatment provided to each group of participants, meaning multiple new drugs can be tested in a short period.  

Glioblastomas are the most common type of cancerous brain tumour in adults, but due to the unique biology of the brain, finding new treatments has proven difficult. 

To help address this, Cancer Research UK and Minderoo Foundation are each committing £1.68m (£3.36m total) to fund the ‘next-Generation aGile Genomically Guided Glioma platform trial’, also known as the 5G platform trial. 

The 5G platform trial is sponsored by The Institute of Cancer Research, London, and conducted by the Joint Drug Development Unit at The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research (ICR).  

​Chief Executive of Cancer Research UK, Michelle Mitchell said: “Brain tumours are notoriously hard to treat because we still don’t know enough about the biology of the disease, and current treatments are not effective enough. This new trial offers something different because researchers will use the DNA of participants to help them target treatments. Whole genome sequencing tests can give clues about how a cancer may have developed, how it will behave and what treatment options would work best.” 

Genome sequencing allows drug targeting 

Incorporating flexibility into the design of the trial means that the drugs given to patients can be changed as real-time data is collected and incorporated. This both benefits the trial itself and improves the likelihood of a positive outcome for participants.  

Dr Juanita Lopez from the Institute of Cancer Research and Dr Richard Mair at the Cancer Research UK Cambridge Institute will co-lead the trial.  

Honorary Consultant Neurosurgeon at Cambridge University Hospitals NHS Foundation Trust and co-lead of the Brain Cancer Virtual Institute at the Cancer Research UK Cambridge Centre, Dr Richard Mair said: “Brain cancers like glioblastoma are notoriously difficult to treat. I am excited to co-lead this world-first trial designed with this cancer type in mind. The use of whole genome sequencing for every patient on the trial performed in ‘real time’ enables us to be both agile and precise in our drug targeting. We hope that this approach will help patients with this cancer of unmet need.”